Eisai and National Cancer Center partner for tazemetostat clinical research
Pharmaceutical Technology
APRIL 3, 2023
Eisai and the National Cancer Center have signed an agreement to partner on investigator-initiated clinical research for the anti-cancer agent, tazemetostat (Tazverik Tablets 200 mg), based on the Patient-Proposed Healthcare Services system.
Let's personalize your content